Marisa Wexler, MS,  senior science writer—

ALS News Today brought consistent coverage of the latest research developments and advances in treatment related to amyotrophic lateral sclerosis (ALS) throughout 2022. We look forward to continuing to serve as a resource for the ALS community in the new year. Here, we’ve compiled a list of the…

Eikonoklastes Therapeutics and Forge Biologics have announced a new partnership to advance the development of ET-101, an experimental gene therapy for amyotrophic lateral sclerosis (ALS), toward clinical trial testing. Eikonoklastes acquired the rights to ET-101 from the University of California San Diego earlier this year. Under…

The COURAGE-ALS Phase 3 clinical trial, testing Cytokinetic’s experimental therapy reldesemtiv in people with amyotrophic lateral sclerosis (ALS), is expected to enroll patients who are most likely to benefit from the potential treatment. That’s according to a new analysis of data from an earlier Phase 2 study of reldesemtiv called…

Higher levels of inflammatory immune cells called effector T-cells at the time of diagnosis are associated with faster disease progression and worse survival among people with amyotrophic lateral sclerosis (ALS), a new study indicates. In turn, greater numbers of regulatory T-cells, which work to dampen excessive immune responses, were…

The European Medicines Agency (EMA) has agreed to review an application seeking the approval of tofersen in treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, the therapy’s developer, Biogen, reported. “Today’s announcement is an important milestone for the ALS community in Europe where there is a tremendous need…

A soft robotic implantable device that can exert mechanical force on muscles was shown to reduce muscle atrophy in a mouse model in a recent study. Based on the findings, researchers believe the device may be able to be applied in diseases such as amyotrophic lateral sclerosis (ALS) that…

An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease progression and extend survival among people with amyotrophic lateral sclerosis (ALS). The oral compound, also known as TUDCA, is one of the two ingredients in Relyvrio (sodium phenylbutyrate…

People who took part in clinical testing of NurOwn, a cell therapy for amyotrophic lateral sclerosis (ALS), and family members have sent a letter in support of Brainstorm Cell Therapeutics and its investigational therapy to the U.S. Food and Drug Administration (FDA). They are also asking for an…

An international team of researchers discovered how, during development, motor neurons — the nerve cells controlling movement whose death causes amyotrophic lateral sclerosis (ALS) — direct blood vessel growth around them while growing toward target muscles. Specifically, motor neurons were found to secrete a combination of signaling molecules that…

NeuroSense Therapeutics has received the go-ahead to begin enrolling patients in the U.S. and Italy for a Phase 2b clinical trial testing PrimeC, the company’s experimental therapy for amyotrophic lateral sclerosis (ALS). The clinical trial, called PARADIGM (NCT05357950), enrolled its first participant in June. The study is…